Potential future therapies for psoriasis

Semin Cutan Med Surg. 2005 Mar;24(1):58-63. doi: 10.1016/j.sder.2005.01.005.
No abstract available

Publication types

  • Review

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Biological Products / therapeutic use*
  • Cyclosporine / therapeutic use*
  • Dermatologic Agents / therapeutic use*
  • Forecasting
  • Fumarates / therapeutic use
  • Humans
  • Infliximab
  • Nicotinic Acids / therapeutic use
  • Psoriasis / therapy*
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Receptors, Tumor Necrosis Factor, Type I
  • Tacrolimus / analogs & derivatives
  • Tacrolimus / therapeutic use
  • Tumor Necrosis Factor Decoy Receptors
  • Ustekinumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Dermatologic Agents
  • Fumarates
  • Nicotinic Acids
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type I
  • Tumor Necrosis Factor Decoy Receptors
  • recombinant human tumor necrosis factor-binding protein-1
  • voclosporin
  • pimecrolimus
  • tazarotene
  • Cyclosporine
  • fumaric acid
  • Infliximab
  • Ustekinumab
  • Adalimumab
  • Tacrolimus